Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Christoph Rollig, MD MSC, Hubert Serve, Andreas Hüttmann, MD, Richard Noppeney, MD, Carsten Müller-Tidow, Utz Krug, Claudia D. Baldus, MD, Christian H. Brandts, MD, Volker Kunzmann, MD PhD, Hermann Einsele, Alwin Krämer, MD, Kerstin Schäfer-Eckart, MD, Andreas Neubauer, MD, Andreas Burchert, MD, Aristoteles Giagounidis, MD, Stefan W. Krause, Andreas Mackensen, MD, Walter E. Aulitzky, MD, Regina Herbst, MD, Mathias Hänel, MD, Alexander Kiani, Norbert Frickhofen, MD, Johannes Kullmer, Ulrich Kaiser, MD, Hartmut Link, MD PhD, Thomas Geer, MD, Albrecht Reichle, MD, Christian Junghanss, MD, Roland Repp, MD, Frank Heits, MD, Heinz Albert Durk, Thomas Illmer, Martin Bornhäuser, MD, Markus Schaich, MD, Stefani Barbara Parmentier, MD, Martin Goerner, MD, Christian Thiede, MD, Malte von Bonin, MD, Johannes Schetelig, MD, Michael Kramer, M.Sc., Wolfgang E. Berdel, Gerhard Ehninger

Blood (2017) 130 (Supplement 1): 721.

https://doi.org/10.1182/blood.V130.Suppl_1.721.721

Published: 2017

Journal Articles

Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial

Julia Winkler, MD, Hannes Tittlbach, Wolf Roesler, MD, Julian Strobel, MD, Roland Zimmermann, MD, Stefanie Maas, MD, Bernd Spriewald, MD, Daniel Wolff, MD, Roland Repp, MD, Lambros Kordelas, MD, Michael Mach, PhD, Andreas Mackensen, MD, Thomas H. Winkler, PhD

Blood (2016) 128 (22): 502.

https://doi.org/10.1182/blood.V128.22.502.502

Published: 2016

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Carsten Müller-Tidow, MD, Petra Tschanter, MD, Utz Krug, MD, Stefanie Goellner, PhD, Christoph Röllig, MD, Christian Thiede, MD, Anja Koschmieder, Martin Dugas, PhD, Joachim Gerss, PhD, Trude Butterfaß-Bahloul, Ruth Wagner, Stefan W. Krause, MD, Ulrich Kaiser, Volker Kunzmann, MD, Björn Steffen, MD, Richard Noppeney, MD, Wolfgang Herr, MD, Claudia D Baldus, Norbert Schmitz, MD, Katharina Götze, Albrecht Reichle, Martin Kaufmann, MD, Andreas Neubauer, MD, Kerstin Schäfer-Eckart, MD, Mathias Hänel, MD, Rudolf Peceny, MD, Haack Bea, Lilly Meredith, Norbert Frickhofen, MD, Michael G Kiehl, MD, Aristoteles A.N. Giagounidis, MD PhD, Martin Görner, Roland Repp, MD, Ralph Naumann, MD, Hartmut Link, MDPhD, Alexander Kiani, MD, Steffen Koschmieder, MD, Tim H. Brümmendorf, MD, Hubert Serve, MD, Gerhard Ehninger, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 946.

https://doi.org/10.1182/blood.V124.21.946.946

Published: 2014

Journal Articles

Maturation of Monocyte-Derived Dendritic Cells Induced by Dual Targeting of Endocytosis Receptor and CD40

Matthias Staudinger, PhD, Inga Rebekka Catenhusen, Matthias Peipp, PhD, Christian Kellner, PhD, Roland Repp, MD, Martin Gramatzki, MD

Blood (2010) 116 (21): 4293.

https://doi.org/10.1182/blood.V116.21.4293.4293

Published: 2010

Journal Articles

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Eugene A. Zhukovsky, PhD, Holly Horton, Ph.D, Matthias Peipp, PhD, Erik Pong, BS, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Seung Chu, PhD, Roland Repp, MD, John Desjarlais, PhD

Blood (2008) 112 (11): 881.

https://doi.org/10.1182/blood.V112.11.881.881

Published: 2008

Journal Articles

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Eugene Zhukovsky, PhD, Seung Chu, PhD, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Erik Pong, BS, Matthias Peipp, PhD, Roland Repp, MD, John Desjarlais, PhD

Blood (2007) 110 (11): 2335.

https://doi.org/10.1182/blood.V110.11.2335.2335

Published: 2007

Journal Articles

Efficient Lysis of Myeloma Cells by CD16 Positive Effector Cells with Recombinant Single Chain Bispecific Antibodies Targeting HM1.24.

Matthias Peipp, PhD, Claudia Ehlert, Matthias Staudinger, PhD, Joerg Bruenke, PhD, Georg Fey, PhD, Martin Gramatzki, MD, Roland Repp, MD

Blood (2007) 110 (11): 2752.

https://doi.org/10.1182/blood.V110.11.2752.2752

Published: 2007

Journal Articles

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Martin H. Dreyling, MD, Roswitha Forstpointner, MD, Hans-Peter Boeck, MD, Roland Repp, MD, Hannes Wandt, MD, Christiane Pott, MD, John Francis Seymour, MD, Bernd Metzner, MD, Annette Haenel, MD, Tanja Lehmann, MD, Frank Hartmann, MD, Hermann Einsele, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 2769.

https://doi.org/10.1182/blood.V108.11.2769.2769

Published: 2006

Journal Articles

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Juergen Rech, MD, Roland Repp, MD, Dorit Rech, MD, Bernhard Stockmeyer, MD, Michael Dechant, MD, Gerald Niedobitek, MD, Tilman Pearce, MD, Georg Weiner, MD, Martin Gramatzki, MD, Thomas Valerius, MD.

Blood (2005) 106 (11): 4775.

https://doi.org/10.1182/blood.V106.11.4775.4775

Published: 2005

Journal Articles

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Matthias Peipp, PhD, Michel de Weers, PhD, Thomas Beyer, PhD, Roland Repp, MD, Paul Parren, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD

Blood (2005) 106 (11): 3377.

https://doi.org/10.1182/blood.V106.11.3377.3377

Published: 2005

Journal Articles

Long Term Remission in Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) with Rituximab Consolidation after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Extended Follow-Up of a Multicenter Phase II Study.

Wolfram Brugger, MD, Judith Hirsch, MD, Roland Repp, MD, Gruenebach Frank, PhD, Schlimok Guenther, MD, Vogel Wichard, MD, Manz Markus, MD, Brossart Peter, MD, Martin Kaufmann, MD, Arnold Ganser, MD, Karl Fehnle, MD, Martin Gramatzki, MD, Lothar Kanz, MD

Blood (2005) 106 (11): 2078.

https://doi.org/10.1182/blood.V106.11.2078.2078

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Maturation of Monocyte-Derived Dendritic Cells Induced by Dual Targeting of Endocytosis Receptor and CD40

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Efficient Lysis of Myeloma Cells by CD16 Positive Effector Cells with Recombinant Single Chain Bispecific Antibodies Targeting HM1.24.

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Long Term Remission in Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) with Rituximab Consolidation after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Extended Follow-Up of a Multicenter Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only